CCTG HN11 SELECT has now opened to accrual across Canada and sites in the US. The trial is a randomized, controlled, phase III clinical trial for patients with lateralized oropharyngeal carcinoma (OPC)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma
The recently launched Centre for Health Innovation, aims to connect researchers from across multiple disciplines to tackle the most pressing human health challenges. A critical part of the centre will be a new home for the CCTG Tumour Tissue Data Repository and includes a large-scale expansion of its histopathology and biobanking resources.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (RAINBO BLUE & TAPER)
Archived Bulletins
The Roster Interface Program & Participants List Environment (Ripple) is a single electronic system which permits:
Canadian Cancer Statistics provides comprehensive surveillance statistics on cancer in Canada. The full publication is produced every second year and includes detailed statistics on incidence, mortality and survival by sex, age group, geographic region and time period for 20+ cancer types.
Adjuvant Palbociclib for ER+ Breast Cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A Preplanned Analysis of the Stage IIA Cohort
